Kura Oncology (KURA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Kura Oncology Reports Second Quarter 2023 Financial Results
August 3, 2023 4:05 PM EDTEnrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections
First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML
Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA
Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC
First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023
$477 million in cash, equivalents and investments provide runway to mid-2026
Management to host webcast and... More
